Novartis Reports Patients with Aggressive Form of Melanoma Lived Average of Two+ Years When Taking Tafinlar + Mekinist

Novartis (NYSE: NVS) today announced updated data from the Phase III COMBI-v study showing a significant overall survival benefit for ...